Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study

NCT04630964 is registered in ClinicalTrials.gov with Section for Affective Disorders; Northern Stockholm Psychiatry as lead sponsor.

NCT NCT04630964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04630964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study
Lead sponsor
Section for Affective Disorders; Northern Stockholm Psychiatry
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2021
Completion date
April 18, 2024
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression, major depressive disorder